Physician profile
Kyle E Benson
NPI 1720611544
$1,096.17
in general payments reported to CMS, 2019-2025
10 companies · $858 in 2025
The $858 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $238 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $230.21 | 2024-2025 | Brixadi |
| Indivior INC. | $189.00 | 2024-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $183.14 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.61 | 2024-2025 | Caplyta |
| Corium, LLC | $95.86 | 2025 | Azstarys |
| Alkermes, INC. | $62.62 | 2024-2025 | Vivitrol |
| Axsome Therapeutics, INC. | $61.55 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $60.26 | 2024-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $51.99 | 2025 | Qelbree |
| Tris Pharma INC | $34.93 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.